Joshua M Hare MD
Adult Congenital Heart Disease, Heart Failure & Transplantation
Professor, Medicine, University of Miami Leonard M. Miller School of Medicine
Join to view full profile
1400 NW 12th AvenueSuite AMiami, FL 33136
Phone+1 305-243-1900
Fax+1 305-243-9927
Dr. Hare is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joshua Hare, based in Miami, FL, specializes in Cardiology with subspecialties in Adult Congenital Heart Disease and Heart Failure & Transplantation. He completed his medical education at Johns Hopkins University and his fellowship in Cardiovascular Disease at Brigham and Women's Hospital. Dr. Hare is a tenured professor at the University of Miami Health System since 2007, with expertise in catheter arrhythmia ablation, heart failure, transplantation, and cardiac genetics. His research includes clinical trials on autologous and allogeneic mesenchymal stem cell therapy for various cardiac conditions. He has been published in several esteemed journals and recognized with awards such as America's Top Doctors and CMS Meaningful Use Certification.
Education & Training
Mass General Brigham/Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1991 - 1994
Johns Hopkins UniversityResidency, Internal Medicine, 1988 - 1991- Johns Hopkins University School of MedicineClass of 1988
Certifications & Licensure
MA State Medical License 1991 - 2028
FL State Medical License 2007 - 2027
MD State Medical License 1995 - 2022
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
Clinical Trials
- Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure
- Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction Start of enrollment: 2005 Mar 22
- Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
Publications & Presentations
PubMed
- Cardiomyocyte-specific expression of HIF-1a mediates the cardioprotective effects of Growth Hormone Releasing Hormone (GHRH).Rosemeire M Kanashiro-Takeuchi, Lauro M Takeuchi, Wayne Balkan, Karina Asensi, Raul A Dulce
American Journal of Physiology. Heart and Circulatory Physiology. 2026-08-01 - LDLR-OPN Interaction Drives COVID-19 Myocarditis Through Monocyte Recruitment.Jose Manuel Condor Capcha, Emely Robleto, Nadia Martinez Naya, Alec Nieth, Pritom Karmaker
JACC. Basic to Translational Science. 2026-06-01 - 1 citationsTargeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide.Fakiha Firdaus, Osmel Companioni Napoles, Raul Ariel Dulce, Anusha Edupuganti, Surinder Kumar
Cell Death Discovery. 2025-11-06
Journal Articles
- Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer GrowthRanjith Ramasamy, Kush Panara, Himanshu Arora, Joshua M Hare, Proceedings of the National Academy of Sciences
- Growth Hormone-Releasing Hormone Attenuates Cardiac Hypertrophy and Improves Heart Function in Pressure Overload-Induced Heart FailureJoshua Hare, MD, Proceedings of the National Academy of Sciences
Press Mentions
‘Demand Is Growing:’ Florida Lab Ramps Up Stem-Cell ProductionMay 17th, 2026- How Hands-on AI Training Accelerates ResearchDecember 10th, 2025
- Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart DefectOctober 27th, 2025
Grant Support
- Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular DiseaseUNIVERSITY OF MIAMI SCHOOL OF MEDICINE2023–2025
- 1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical TrialLURIE CHILDREN'S HOSPITAL OF CHICAGO2020–2025
- Cell Based Therapy For Non-Ischemic Dilated CardiomyopathyNational Heart, Lung, And Blood Institute2012
- Cardioprotective Effect Of Growth Hormone Releasing HormoneNational Heart, Lung, And Blood Institute2011–2012
- Nitroso/Redox Balance In Myocardial InfarctionNational Heart, Lung, And Blood Institute2009–2012
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
